Menostar (Estradiol, BAY86-5435) + Raloxifene
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Osteopenia
Conditions
Osteopenia
Trial Timeline
Feb 1, 2004 → Jun 1, 2007
NCT ID
NCT00310531About Menostar (Estradiol, BAY86-5435) + Raloxifene
Menostar (Estradiol, BAY86-5435) + Raloxifene is a phase 3 stage product being developed by Bayer for Osteopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00310531. Target conditions include Osteopenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00310531 | Phase 3 | Completed |
Competing Products
18 competing products in Osteopenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide + Zoledronic Acid | Eli Lilly | Approved | 85 |
| alendronate sodium | Merck | Approved | 85 |
| zoledronic acid | Novartis | Phase 3 | 77 |
| zoledronic acid vs pamidronate | Novartis | Approved | 85 |
| Zoledronic Acid + Placebo | Novartis | Phase 3 | 77 |
| BPS804 20mg/Kg + Placebo to 20mg/Kg BPS804 | Novartis | Phase 2 | 52 |
| Placebo + ibandronate [Bonviva/Boniva] | Roche | Approved | 85 |
| ibandronate [Bonviva/Boniva] + Placebo | Roche | Phase 3 | 77 |
| Romosozumab + Placebo | Amgen | Phase 1 | 32 |
| Placebo + AMG 167 | Amgen | Phase 1 | 32 |
| AMG 167 + Placebo | Amgen | Phase 1 | 32 |
| Romosozumab + Placebo | Amgen | Phase 1 | 32 |
| Denosumab | Amgen | Phase 3 | 76 |
| Romosozumab + Placebo | Amgen | Phase 1 | 32 |
| Dasatinib 100 Mg Oral Tablet | Novo Nordisk | Phase 2 | 51 |
| RN564 | Pfizer | Phase 1 | 32 |
| risedronate + alendronate | Sanofi | Phase 1 | 32 |
| tibolone + raloxifen | Organon | Approved | 80 |